摘要
目的:观察血脂康对慢性心力衰竭患者心功能、血浆脑钠肽和高敏C反应蛋白水平的影响,评价该药抗心衰疗效,初步探讨其作用机制。方法:80例慢性心力衰竭患者随机分为观察组和对照组,常规抗心衰治疗,观察组加服血脂康,疗程8周。治疗前后用彩超测定左心室射血分数(LVEF)和左心室舒张末期内径(LVDd),以ELISA法与散射比浊法分别测定血浆N-末端脑钠肽前体(NT-proBNP)和高敏C反应蛋白(HS-CRP)水平。结果:治疗后观察组总有效率明显高于对照组,LVEF明显升高、LVDd明显下降,血浆NT-proBNP、HS-CRP水平均明显下降;观察组血浆NT-proBNP与LVEF呈负相关(r=-0.72,P<0.05),与LVDd呈正相关(r=0.75,P<0.05);血浆HS-CRP水平与LVDd呈正相关(r=0.31,P<0.05),与LVEF增加呈负相关(r=-0.387,P<0.05)。结论:血脂康能降低血浆NT-proBNP、HS-CRP水平,抑制左心室重构,改善心脏功能,在慢性心力衰竭防治中起重要作用;其作用机制可能与改善神经体液功能有关。
AIM:To observe the cardiac protection effect of Xuezhikang on cardiac function in patients with chronic heart failure(CHF) and its relation with plasma N-terminal pro-brain natriuretic peptide(NT-proBNP) and high-sensitivity high-sensitivity C-reactive protein(HS-CRP) levels. METHODS:80 patients with CHF were randomly divided into two groups;the control group received routine anti-failure treatment,and the observation group received routine anti-failure treatment in combination with Xuezhikang for 8 weeks.The cardiac function,i.e.,left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVDd),were measured before and after treatment with color Doppler ultrasound;plasma NT-proBNP,HS-CRP levels were determined by ELISA method and nephelometry respectively.RESULTS:The cardiac function improved more effectively in the observation group than that in the control group.The LVEF increasing and LVDd decreasing were correlated to plasma NT-proBNP levels(r=-0.72 and 0.75,P0.05 respectively) and HS-CRP levels(r=-0.387 and 0.31,P0.05).CONCLUSION:Xuezhikang is effective in anti-failure treatment.Reducing plasma NT-proBNP and HS-CRP levels may be the possible mechanism of the drug,but NT-proBNP reducing is more important.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2010年第11期1284-1287,共4页
Chinese Journal of Clinical Pharmacology and Therapeutics
关键词
慢性心力衰竭
N-末端脑钠肽前体
高敏C反应蛋白
血脂康
Chronic heart failure
N-terminal pro-brain natriuretic peptide
High-sensitivity C-reactive protein
Xuezhikang